“十四五”胶质瘤基础与转化研究目标与共识  

Goals and Consensus of Basic and Translational Research on Glioma during China’s 14th Five-Year Plan(2021—2025)

作　　者：崔晓腾 方川[2] 刘博杨 叶敏华[4] 曾亮 万锋[5] 谢琦 汪强虎 汪秀星 檀艳丽[9] 周秀萍 吴旭东 李学军[12] 郭洪波[3] 尤永平[13] 康春生[1] CUI Xiaoteng;FANG Chuan;LIU Boyang;YE Minhua;ZENG Liang;WAN Feng;XIE Qi;WANG Qianghu;WANG Xiuxing;TAN Yanli;ZHOU Xiuping;WU Xudong;LI Xuejun;GUO Hongbo;YOU Yongping;KANG Chunsheng(Tianjin Neurological Institute,Tianjin Medical University General Hospital,Tianjin 300052,China;Department of Neurosurgery,Affiliated Hospital of Hebei University,Baoding 071030,China;Department of Neurosurgery,Zhujiang Hospital of Southern Medical University,Guangzhou 510282,China;Department of Neurosurgery,Second Affiliated Hospital of Nanchang University,Nanchang 330006,China;Department of Neurosurgery,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Institute of Basic Medical Sciences,Westlake University,Hangzhou 310024,China;School of Biomedical Engineering and Informatics,Nanjing Medical University,Nanjing 211166,China;School of Basic Medical Science,Nanjing Medical University,Nanjing 211166,China;Department of Pathology,Affiliated Hospital of Hebei University,Baoding 071030,China;Brain Hospital,Affiliated Hospital of Xuzhou Medical University,Institute of Nervous System Diseases,Xuzhou Medical University,Xuzhou 221006,China;Department of Cell Biology,School of Basic Medical Sciences,Tianjin Medical University,Tianjin 300070,China;Department of Neurosurgery,Xiangya Hospital,Central South University,Changsha 410008,China;Department of Neurosurgery,The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]天津医科大学总医院天津市神经病学研究所,天津300052 [2]河北大学附属医院神经外科,河北保定071030 [3]南方医科大学珠江医院神经外科,广东广州510282 [4]南昌大学第二附属医院神经外科,江西南昌330006 [5]华中科技大学同济医学院附属同济医院神经外科,湖北武汉430030 [6]西湖大学生命科学学院,浙江杭州310024 [7]南京医科大学生物医学工程与信息学院,江苏南京211166 [8]南京医科大学基础医学院,江苏南京211166 [9]河北大学附属医院病理科,河北保定071030 [10]徐州医科大学附属医院脑科医院徐州医科大学神经系统疾病研究所,江苏徐州221006 [11]天津医科大学基础医学院细胞生物学系,天津300070 [12]中南大学湘雅医院神经外科,湖南长沙410008 [13]南京医科大学第一附属医院神经外科,江苏南京210029

出　　处：《药学进展》2021年第12期927-932,共6页Progress in Pharmaceutical Sciences

基　　金：天津市科技支撑重点项目(No.20YFZCSY00360);河北省精准医学联合基金重点项目(No.H2020201206);国家自然科学基金面上项目(No.81974389,No.81772679)。

摘　　要：国家“十四五”发展规划和2035年远景目标纲要提出,把保障人民健康放在优先发展的战略位置,全面推进健康中国建设。目前,我国神经系统肿瘤的发病人数和死亡人数均居世界首位,严重威胁我国人民身体健康。在此大背景下,中国医师协会脑胶质瘤专业委员会基础研究与转化学组整理总结目前胶质瘤研究进展,着眼于全新诊断治疗的策略突破、发病和耐药机制的深层次研究、全新胶质瘤动物模型的开发探索以及我国胶质瘤标准化资源共享平台的建立,旨在阐明中国胶质瘤研究方向,加速推动胶质瘤基础研究到临床应用的转化突破,实现科研成果从专利到临床转化的整体管线布局。The"14th Five-Year Development Plan”(2021-2025)and the outline of long-term goals for 2035 in China put to priority the protection of people's health and construction of a“healthy China”in an all-round way.At present,the morbidity and mortality of nervous system tumors in China rank first in the world,which seriously threatens the health of the Chinese people.In this context,the basic and translational research group of Glioma Specialized Committee of the Chinese Medical Association reviewed and summarized the current research progress of glioma,focusing on the breakthroughs of new diagnostic and therapeutic strategies,the in-depth study of pathogenesis and drug resistance mechanisms,the development and exploration of new glioma animal models,and the establishment of glioma standardized resource sharing platform in China,so as to clarify the research direction of glioma in China,accelerate the translation from basic research to clinical application of glioma,and realize the overall pipeline layout of scientific research achievements from patent to clinical application.

关 键 词：胶质瘤 基础与转化研究 专家共识 

分 类 号：R739.4[医药卫生—肿瘤]